While broad level gain of 12p in TGCTs appears likely to confer the pluripotent phenotype for initiation of tumourigenesis, the focal amplification of the region containing SLC2A3 may grant a proliferative advantage in progression and development of the tumour. The gene discussed is SLC2A3; the disease is neoplasm.